Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1977 Dec;30(12):1149–1153. doi: 10.1136/jcp.30.12.1149

Granuloma formation in patients after injection of methanol extraction residue (MER-GCG).

A Bartal, H Kerner, Y Cohen, E Robinson
PMCID: PMC476699  PMID: 604361

Abstract

Nine patients with advanced cancer who were receiving the methanol extraction residue of BCG (MER-BCG) intradermally or intratumorally underwent biopsies from the injected sites or from locally enlarged lymph nodes. Most preparations showed a chronic granulomatous reaction consisting of lymphocytes, histiocytes, and epithelioid cells as well as either Langhans's or foreignbody type giant cells, or both. The degree of granuloma formation and giant cell infiltration varied. In only one case did the reactions consist merely of chronic lymphocytic and histiocytic inflammation with no granuloma formation. Examination of melanoma nodules injected with MER showed, in addition to granulomas, large numbers of giant cells penetrating the tumour.

Full text

PDF
1149

Images in this article

1151Image
on p.1151
1151Image
on p.1151

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
  2. Fisher B., Rubin H., Sartiano G., Ennis L., Wolmark N. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. Cancer. 1976 Jul;38(1):119–130. doi: 10.1002/1097-0142(197607)38:1<119::aid-cncr2820380121>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  3. Granger D. L., Brehmer W., Brehmer W., Yamamoto K., Ribi E. Cutaneous granulomatous response to BCG cell walls with reference to cancer immunotherapy. Infect Immun. 1976 Feb;13(2):543–553. doi: 10.1128/iai.13.2.543-553.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hunt J. S., Silverstein M. J., Sparks F. C., Haskell C. M., Pilch Y. H., Morton D. L. Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet. 1973 Oct 13;2(7833):820–821. doi: 10.1016/s0140-6736(73)90860-x. [DOI] [PubMed] [Google Scholar]
  5. Meyer T. J., Ribi E., Azuma I. Biologically active components from mycobacterial cell walls. V. Granuloma formation in mouse lungs and guinea pig skin. Cell Immunol. 1975 Mar;16(1):11–24. doi: 10.1016/0008-8749(75)90181-1. [DOI] [PubMed] [Google Scholar]
  6. Mitchell M. S. Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications. Biomedicine. 1976;24(4):209–213. [PubMed] [Google Scholar]
  7. Muggleton P. W., Prince G. H., Hilton M. L. Effect of intravenous B.C.G. in guineapigs and pertinence to cancer immunotherapy in man. Lancet. 1975 Jun 21;1(7921):1353–1355. doi: 10.1016/s0140-6736(75)92261-8. [DOI] [PubMed] [Google Scholar]
  8. Robinson E., Bartal A., Cohen Y., Haasz R. A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients. Br J Cancer. 1975 Jul;32(1):1–4. doi: 10.1038/bjc.1975.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Weiss D. W. Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli. Natl Cancer Inst Monogr. 1972 Dec;35:157–171. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES